• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop nanodiscs to deliver personalized cancer therapy

December 28, 2016 By Sarah Faulkner

Researchers develop nanodiscs to deliver personalized cancer therapyResearchers from the University of Michigan have developed nanodiscs that deliver a customized therapeutic vaccine to treat colon and melanoma cancer in mice. The team’s work was published in Nature Materials.

“We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” senior author James Moon said in prepared remarks.

The team loaded the nanodiscs with unique mutations founds in tumor cells and generated T-cells to recognize the specific mutations in order to target the tumor. “The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner,” Moon explained.

After the team gave the nanodisc vaccine to mice with melanoma and colon cancer tumors, they observed that 27% of T-cells in the mice’s blood targeted the tumors. When the nanodisc was combined with immune checkpoint inhibitors, the treatment killed tumors within 10 days of treatment.

After 70 days, researchers injected the same mice with the tumor cells that were extracted from the tumor they previously had and saw that the tumors were rejected by the immune system. “This suggests the immune system ‘remembered’ the cancer cells for long-term immunity,” lead researcher Rui Kuai said.

“The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice,” Moon added. The team’s next step will be to test the vaccine in a larger animal model.

A spinoff biotech company, EVOQ Therapeutics, was founded to translate the team’s results to the clinic.

Filed Under: Featured, Immunotherapy, Nanoparticles, Oncology, Research & Development Tagged With: University of Michigan

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS